Chandler Park, Advisory Dean and Clinical Professor at University of Louisville School of Medicine, shared a post on LinkedIn:
“Congratulations to Dr. Sara Tolaney, Dana-Farber Cancer Institute and the Destiny Breast09 investigators for a Trasnformative study for 1st line metastatic HER2+ breast cancer at ASCO25.
Really enjoyed talking to Dr. Giuseppe Curigliano on the HER2 story that started in Orlando about 20 years ago.”
Chandler Park acknowledged the impact of the DESTINY-Breast09 trial presented at ASCO 2025, recognizing Dr. Sara Tolaney and the investigative team for advancing treatment in first-line metastatic HER2-positive breast cancer.
More posts featuring Chandler Park.